Overview

A Study for Patients With Secondary Progressive Multiple Sclerosis

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
BioMS Technology Corp.